Nanomaterials for Photo-Based Diagnostic and Therapeutic Applications

Menon, Jyothi U.; Jadeja, Parth; Tambe, Pranjali; Vu, Khanh B.; Yuan, Baohong; Nguyen, Kytai T.

doi:10.7150/thno.5327

Cited by 252 publications

(156 citation statements)

References 123 publications

Supporting

Mentioning

154

Contrasting

Order By: Relevance

“…Gold nanoparticles consisting of a dielectric core of silica coated with a metallic layer of gold, are available in various sizes and forms (62) and can be used for e.g., as biosensors, or photoactive agents for optical imaging, for photothermal ablation therapy, or as drug carriers. SPIONs consist of iron oxide core, often coated with organic materials such as fatty acids, polysaccharides, or polymers (63,64).…”

Section: Nano-sized Drug Carriersmentioning

confidence: 99%

Cardiovascular therapy through nanotechnology – how far are we still from bedside?

Cicha¹,

Garlichs²,

Alexiou³

2014

European Journal of Nanomedicine

View full text Add to dashboard Cite

Abstract:Recent years brought about a widespread interest in the potential applications of nanotechnology for the diagnostics and the therapy of human diseases. With its promise of disease-targeted, patient-tailored treatment and reduced side effects, nanomedicine brings hope for millions of patients suffering of non-communicable diseases such as cancer or cardiovascular disorders. However, the emergence of the complex, multicomponent products based on new technologies poses multiple challenges to successful approval in clinical practice. Regulatory and development considerations, including properties of the components, reproducible manufacturing and appropriate characterization methods, as well as nanodrugs' safety and efficacy are critical for rapid marketing of the new products. This review discusses the recent advances in cardiovascular applications of nanotechnologies and highlights the challenges that must be overcome in order to fill the gap existing between the promising bench trials and the successful bedside applications.

show abstract

Section: Nano-sized Drug Carriersmentioning

confidence: 99%

Cardiovascular therapy through nanotechnology – how far are we still from bedside?

Cicha¹,

Garlichs²,

Alexiou³

2014

European Journal of Nanomedicine

View full text Add to dashboard Cite

show abstract

“…This derives from the use of MBs as fluorescent probes with high target specificity [132,133]. The PS is linked to a quenching molecule, so that it is inactive until the linker is cleaved by a target-specific enzyme.…”

Section: Delivery and Selectivity Of Psmentioning

confidence: 99%

Basic and Clinical Aspects of Photodynamic Therapy

Rapozzi

Jori

2014

Resistance to Targeted Anti-Cancer Therapeutics

View full text Add to dashboard Cite

Photodynamic therapy (PDT) was originally developed for the treatment of solid tumors by the concerted action of a tumor-localizing agent, named as the photosensitizer, molecular oxygen and visible light source. The photoinduced cytotxic species are mainly represented by singlet oxygen ( 1 O 2 ), even though the formation of NO has been observed in selected situations. Optimal results are generally obtained by using porphyrins and their tetrapyrrolic analogues as the photodynamic agents, since these compounds display an intense absorbance of the red spectra wavelengths, which are endowed with a particularly deep penetration into most biological tissues. While several porphyrins exhibit an intrinsic preferential affinity for malignant tissues, the selectivity of the tumor localization can be significantly enhanced by pre-binding the photosensitizer with a targeting agent, such as an antibody or a vehicle (e.g., glycoproteins, peptides, oligonucleotide aptamers, growth factors, lipoproteins) directed against antigens or receptors which are specifically present at the surface of tumor cells. Recently, novel perspectives have been opened by the association of the photosensitizer with nanoparticles, which can be made to be multifunctional, thereby allowing the simultaneous delivery of photoactivatable moieties acting by different mechanisms, as well as of phototherapeutic and photodiagnostic agents. The chemical structure of the photosensitizer and the nature of the possible carrier have important consequences with regards to the distribution of the photosensitizer among different compartments of the tumor tissue, such as neoplastic cells, blood vessels or the non-vascular stroma, as well as its localization in different subcellular sites; these would obviously affect the mechanism of photoinduced tumor damage, modulating the competition between necrosis, apoptosis and autophagia, the importance of photoinduced hypoxia, and the balance between enhancement of the immune response and immunosuppression. So far, about 250 randomized clinical trials have been officially reported for 4 V. Rapozzi and G. Jori PDT of tumors, and essentially all types of solid tumors with the exception of melanotic melanoma have been found to be positively responsive to the photodynamic treatment. Thus, PDT is currently considered as a reasonable option for the treatment of a variety of malignant lesions for curative or palliative purposes by using either external or endoscopic irradiation approaches via non-coherent or laser light sources.

show abstract

“…20,21 Poly (d,l-lactide-co-glycolide) (PLGA), a biodegradable and biocompatible synthetic polymer approved by the US Food and Drug Administration, is widely used in drug delivery system. [22][23][24] Various studies have reported that multiple drug resistance could be overcome by PLGA NPs codelivering anticancer drug and p-gp inhibitors, indicating that PLGA NPs may be a promising approach to overcome drug resistance. 25 Recently, a surge of interest using pluronic block copolymers, which consist of p-gp inhibitors to reverse drug resistance, has emerged due to their unique properties in the inhibition of drug efflux pump.…”

Section: Introductionmentioning

confidence: 99%

A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

Ji¹,

Chen²,

Bao³

et al. 2016

IJN

View full text Add to dashboard Cite

Drug resistance has become a main obstacle for the effective treatment of lung cancer. To address this problem, a novel biocompatible nanoscale package, poly( d , l -lactide- co -glycolide)-Tween 80, was designed and synthesized to overcome paclitaxel (PTX) resistance in a PTX-resistant human lung cancer cell line. The poly( d , l -lactide-co-glycolide) (PLGA)-Tween 80 nanoparticles (NPs) could efficiently load PTX and release the drug gradually. There was an increased level of uptake of PLGA-Tween 80 in PTX-resistant lung cancer cell line A549/T, which achieved a significantly higher level of cytotoxicity than both PLGA NP formulation and Taxol ® . The in vivo antitumor efficacy also showed that PLGA-Tween 80 NP was more effective than Taxol ® , indicating that PLGA-Tween 80 copolymer was a promising carrier for PTX in resistant lung cancer.

show abstract

Nanomaterials for Photo-Based Diagnostic and Therapeutic Applications

Cited by 252 publications

References 123 publications

Cardiovascular therapy through nanotechnology – how far are we still from bedside?

Cardiovascular therapy through nanotechnology – how far are we still from bedside?

Basic and Clinical Aspects of Photodynamic Therapy

A novel paclitaxel-loaded poly(D,L-lactide-co-glycolide)-Tween 80 copolymer nanoparticle overcoming multidrug resistance for lung cancer treatment

Contact Info

Product

Resources

About